10-Q: ZimVie Inc. Reports Second Quarter 2024 Results Following Spine Business Divestiture

ZimVie Inc. reports a net loss for the second quarter of 2024, impacted by the recent sale of its spine business, while focusing on its core dental operations.

Summary

• ZimVie Inc. reported a net loss of $4.014 million for the three months ended June 30, 2024, and a net loss of $11.775 million for the six months ended June 30, 2024.
• The company completed the sale of its spine segment on April 1, 2024, for a total purchase price of $377.2 million, receiving $311.8 million in cash and a $60 million promissory note.
• Net sales for the three months ended June 30, 2024, were $116.811 million, a decrease of 1.5% compared to the same period in 2023.
• Net sales for the six months ended June 30, 2024, were $235.006 million, a decrease of 1.7% compared to the same period in 2023.
• The company's operating loss for the three months ended June 30, 2024, was $6.687 million, compared to $4.388 million in 2023.
• The operating loss for the six months ended June 30, 2024, was $9.498 million, compared to $10.599 million in 2023.
• The company incurred restructuring charges of $0.4 million and $2.8 million for the three and six months ended June 30, 2024, respectively, related to organizational changes following the spine segment sale.
• The company's cash and cash equivalents were $82.695 million as of June 30, 2024.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the reported net loss and revenue decline, although the company has taken positive steps to reduce debt and focus on its core business. The outlook is uncertain due to pricing pressures and market volatility.

Positives

• The sale of the spine segment generated $311.8 million in cash, which was used to reduce debt.
• The company is now focused on its core dental business, which has market-leading positions in certain geographies.
• The company has reduced its debt by $275 million using proceeds from the sale of the spine segment.
• The company is streamlining its organizational infrastructure to support the dental segment.

Negatives

• The company reported a net loss of $4.014 million for the quarter and $11.775 million for the first six months of 2024.
• Net sales decreased by 1.5% in the second quarter and 1.7% in the first six months of 2024 compared to the same periods in 2023.
• The company experienced pricing pressures on premium dental implant system sales in North America and in China.
• The company incurred restructuring charges of $0.4 million and $2.8 million for the three and six months ended June 30, 2024, respectively.

Risks

• The company is now more reliant on its dental business, making it more vulnerable to market changes.
• The company faces pricing pressures in the dental implant market, particularly in North America and China.
• The company's ability to collect accounts receivable in some countries depends on the financial stability of the healthcare sectors and national economic systems.
• The company is subject to various claims, legal proceedings, and investigations that could have a material adverse impact on its financial results.

Future Outlook

The company believes that available cash and cash equivalents, cash flows generated through operations, and cash available under its revolving credit facility will be sufficient to meet its liquidity needs for at least the next 12 months. The company is focused on its core dental business and streamlining its operations.

Management Comments

• The company is focused on its core dental business following the sale of the spine segment.
• The company is streamlining its organizational infrastructure to support the dental segment.
• The company believes it has sufficient liquidity to meet its needs for the next 12 months.

Industry Context

The medical technology industry is experiencing consolidation and pricing pressures, particularly in the dental implant market. ZimVie's divestiture of its spine business and focus on dental aligns with a trend of companies streamlining their portfolios to focus on core competencies. The company is facing similar challenges to its competitors in terms of pricing and market dynamics.

Comparison to Industry Standards

• ZimVie's revenue decline of 1.5% in the second quarter is below the average growth rate for the medical device industry, which has seen modest growth in recent quarters.
• The company's operating loss of $6.687 million for the quarter is worse than some of its competitors who have reported profits or smaller losses.
• The company's focus on dental is similar to other companies that have divested non-core assets to focus on higher-growth areas.
• The company's debt reduction of $275 million is a positive step compared to some competitors who are carrying higher debt loads.

Legal Proceedings

• The company is subject to various claims, legal proceedings, and investigations regarding product liability, intellectual property, commercial, and other matters that arise in the normal course of business.

Stakeholder Impact

• Shareholders are impacted by the reported net loss and revenue decline.
• Employees are impacted by the restructuring activities and potential job losses.
• Customers may be impacted by changes in product offerings and pricing.
• Suppliers may be impacted by changes in the company's supply chain.

Next Steps

• The company will continue to focus on its core dental business.
• The company will continue to streamline its organizational infrastructure.
• The company will monitor market conditions and pricing pressures.

Key Dates

Keywords

dental implants, spine business, divestiture, restructuring, net sales, net loss, promissory note, debt reduction, operating loss, ZimVie